Education
About Us
Working with TipRanks
Follow Us
Cumberland Pharmaceuticals Inc (CPIX)
NASDAQ:CPIX
Top Page
Cumberland Pharmaceuticals
(NASDAQ:CPIX)
Rating:52Neutral
Price Target:
$3.50
▲(5.74% Upside)
Cumberland Pharmaceuticals (CPIX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$54.75M
Dividend YieldN/A
Average Volume (3M)63.27K
Price to Earnings (P/E)―
Beta (1Y)-0.56
Revenue Growth11.34%
EPS Growth71.13%
CountryUS
Employees91
SectorHealthcare
Sector Strength51
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.05
Shares Outstanding14,959,937
10 Day Avg. Volume34,786
30 Day Avg. Volume63,266
Financial Highlights & Ratios
PEG Ratio-1.13
Price to Book (P/B)1.46
Price to Sales (P/S)0.88
P/FCF Ratio-42.08
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue1.05
Enterprise Value/Gross Profit1.25
Enterprise Value/Ebitda13.74
Forecast
1Y Price Target
$3.50Price Target Upside5.74% Upside
Rating ConsensusHold
Number of Analyst Covering1
Cumberland Pharmaceuticals Business Overview & Revenue Model
Company DescriptionCumberland Pharmaceuticals Inc. (CPIX) is a specialty pharmaceutical company focused on acquiring, developing, and commercializing innovative products for the hospital and related healthcare markets. The company primarily operates in the sectors of pain management and critical care, with a portfolio that includes FDA-approved products such as Caldolor, a therapeutic option for pain and fever, and other treatments aimed at improving patient outcomes in complex medical situations.
How the Company Makes MoneyCumberland Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products to hospitals, healthcare providers, and distributors. The company has established a revenue model that includes direct sales, distribution agreements, and partnerships with other pharmaceutical companies. Significant revenue streams arise from its marketed products, particularly in the areas of pain management and critical care. Additionally, the company may receive royalties or milestone payments from collaborations in research and development, further enhancing its earnings potential.
Cumberland Pharmaceuticals Earnings Call Summary
Earnings Call Date:Aug 05, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth, positive clinical trial results for ifetroban, successful international expansion of Vibativ, and new strategic partnerships. No major challenges or negative trends were reported, suggesting a strong positive outlook for Cumberland Pharmaceuticals.Q2-2025 Updates
Positive Updates
Strong Revenue Growth
Cumberland Pharmaceuticals reported a 10% increase in revenue for the second quarter of 2025, totaling $10.8 million. Year-to-date revenues for the first 6 months reached $22.6 million, marking a 23% increase over the prior year period.
Positive Clinical Developments for Ifetroban
Ifetroban showed a 5.4% improvement in cardiac functions for patients with Duchenne muscular dystrophy (DMD) and reduced cardiac damage biomarkers, positioning it as a potential treatment for DMD cardiomyopathy.
International Expansion of Vibativ
Vibativ received approval from Chinese regulatory authorities and is preparing for launch in China and the Middle East through a partnership with Tabuk Pharmaceuticals.
New Partnerships and Product Launches
Cumberland announced a new partnership with Qureight for deep learning image analytics to enhance clinical trial outcomes and a new distribution partnership with Vizient, providing access to Vibativ's 4-vial configuration.
Negative Updates
No Major Challenges Reported
The earnings call did not highlight any significant challenges or negative trends affecting Cumberland Pharmaceuticals during the second quarter of 2025.
Company Guidance
During the Cumberland Pharmaceuticals second quarter 2025 financial report call, several key metrics and developments were highlighted. The company reported a 10% increase in quarterly revenues, reaching $10.8 million, compared to the same period last year. Year-to-date revenues for the first half of 2025 totaled $22.6 million, marking a 23% increase from the prior year. Adjusted earnings for the second quarter were reported at $0.4 million, with a year-to-date figure of $2.8 million or $0.18 per share. The company's portfolio of FDA-approved brands contributed to these results, including Vibativ, which saw regulatory approval in China and a new partnership in the Middle East. The company's balance sheet at the end of the quarter showed $68 million in total assets, $16 million in cash and cash equivalents, $40 million in liabilities, and $28 million in shareholders' equity. Cumberland's pipeline developments were also discussed, particularly the positive Phase II study results of ifetroban for Duchenne muscular dystrophy, with plans to meet the FDA to discuss further development.Cumberland Pharmaceuticals Financial Statement Overview
Summary
Cumberland Pharmaceuticals shows mixed financial performance. While revenue growth and cash flow improvements are positive, profitability issues persist with negative net profit margins. The balance sheet is stable with manageable debt, but operational efficiency needs improvement.Income Statement
Cumberland Pharmaceuticals shows a mixed performance in its income statement. The company has a positive revenue growth rate of 2.41% TTM, indicating some recovery. However, profitability remains a concern with negative net profit and EBIT margins, reflecting ongoing operational challenges. The gross profit margin is relatively strong at 77.92% TTM, but the negative net profit margin of -7.98% TTM highlights the need for cost control and efficiency improvements.45
Neutral
Balance Sheet
The balance sheet reflects moderate stability with a debt-to-equity ratio of 0.36 TTM, indicating manageable leverage. However, the return on equity is negative at -12.77% TTM, suggesting inefficiencies in generating returns for shareholders. The equity ratio is not explicitly calculated, but the company's equity position appears stable relative to its assets.50
Neutral
Cash Flow
Cash flow analysis shows improvement, with a significant free cash flow growth rate of 32.19% TTM, indicating better cash management. The operating cash flow to net income ratio is 0.21 TTM, suggesting that the company is generating cash from operations despite net losses. The free cash flow to net income ratio is high at 0.99 TTM, reflecting strong cash conversion efficiency.60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.07M | 37.87M | 39.55M | 42.01M | 35.99M | 37.44M |
| Gross Profit | 35.34M | 31.28M | 33.49M | 32.89M | 27.17M | 28.79M |
| EBITDA | 3.21M | 182.42K | 153.32K | 332.92K | -857.83K | -1.56M |
| Net Income | -2.93M | -6.48M | -6.28M | -5.65M | -5.60M | -6.63M |
Balance Sheet | ||||||
| Total Assets | 67.91M | 75.58M | 81.78M | 92.93M | 84.46M | 96.46M |
| Cash, Cash Equivalents and Short-Term Investments | 16.09M | 17.96M | 18.32M | 19.76M | 27.04M | 24.75M |
| Total Debt | 10.34M | 20.57M | 18.43M | 20.96M | 16.06M | 17.08M |
| Total Liabilities | 40.23M | 53.04M | 52.52M | 56.95M | 41.86M | 49.59M |
| Stockholders Equity | 27.99M | 22.85M | 29.60M | 36.27M | 42.81M | 46.99M |
Cash Flow | ||||||
| Free Cash Flow | 7.06M | -791.90K | 5.64M | 6.38M | 5.99M | 3.30M |
| Operating Cash Flow | 7.12M | -612.19K | 6.09M | 8.45M | 6.34M | 5.42M |
| Investing Cash Flow | -779.49K | 57.84K | -105.69K | -13.67M | -501.89K | -1.76M |
| Financing Cash Flow | -7.59M | 196.90K | -7.42M | -2.06M | -3.55M | -7.12M |
Cumberland Pharmaceuticals Technical Analysis
Negative
3.31
Price Trends
3.32
Negative
4.14
Negative
3.77
Negative
Market Momentum
0.03
Negative
47.19
Neutral
64.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPIX, the sentiment is Negative. The current price of 3.31 is above the 20-day moving average (MA) of 3.26, below the 50-day MA of 3.32, and below the 200-day MA of 3.77, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 47.19 is Neutral, neither overbought nor oversold. The STOCH value of 64.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CPIX.
Cumberland Pharmaceuticals Risk Analysis
Cumberland Pharmaceuticals disclosed 1 risk factors in its most recent earnings report. Cumberland Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cumberland Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $77.70M | ― | -38.40% | ― | -11.42% | 89.01% | |
54 Neutral | $57.84M | ― | -8.65% | ― | -6.79% | 61.56% | |
52 Neutral | $54.75M | ― | -10.79% | ― | 11.34% | 71.13% | |
51 Neutral | $7.92B | -0.43 | -41.67% | 2.21% | 22.29% | -1.85% | |
44 Neutral | $36.43M | ― | -37.22% | ― | -66.30% | 50.52% | |
39 Underperform | $54.34M | ― | -201.88% | ― | ― | ― | |
31 Underperform | $102.02M | ― | -708.34% | ― | ― | 51.27% |
* Healthcare Sector Average
Performance Comparison
CPIX
Cumberland Pharmaceuticals
3.31
2.02
156.59%
ASRT
Assertio Therapeutics
0.80
-0.48
-37.50%
RMTI
Rockwell Med
1.62
-1.91
-54.11%
SCYX
SCYNEXIS
0.89
-0.45
-33.58%
KALA
Kala Pharmaceuticals
14.55
8.60
144.54%
IXHL
Incannex Healthcare Limited Sponsored ADR
0.52
-1.09
-67.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.